Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report) today and set a price target of $14.00. The company’s shares closed yesterday at $3.44.
According to TipRanks, LeBoyer is an analyst with an average return of -3.5% and a 27.44% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Axcella Health, and Onconova Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MAIA Biotechnology, Inc. with a $14.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.64 and a one-year low of $3.06. Currently, MAIA Biotechnology, Inc. has an average volume of 26.66K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company’s lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Read More on MAIA:
- MAIA Biotechnology reports no exposure to Silicon Valley Bank
- MAIA Biotechnology doses first two patients in THIO-101 trial
- MAIA Biotechnology initiated with an Outperform at Noble Capital
- MAIA :THIO combo with checkpoint immune therapies showed tumor inhibition
- MAIA Biotechnology files to sell 2.43M shares of common stock
